Project Grant R37CA316700
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $815K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14642, USA
Similar Awards
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $651,545 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the meningeal lymphatic system as a pathogenic driver of chemotherapy-induced cognitive impairment in cancer survivors. The research targets chemobrain, a persistent cognitive dysfunction affecting pediatric and adult cancer survivors whose underlying mechanisms remain...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Rochester $624,494 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate combined stereotactic body radiotherapy and interleukin-12 messenger RNA nanotechnology as a treatment strategy for pancreatic ductal adenocarcinoma. The research targets T cell dynamics in the pancreatic cancer tumor microenvironment by combining localized stereotactic body...
- The National Cancer Institute awarded The Research Foundation For The State University of New York $410,545 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to assess efflux transport, pharmacokinetics, and systems pharmacology impact on monomethyl auristatin E (MMAE)-induced neurotoxicity. MMAE exposure following antibody-drug conjugate (ADC) treatment causes peripheral neuropathy in approximately 50 percent of patients, commonly irreversible and capable of...
- The National Cancer Institute awarded Weill Medical College of Cornell University $465,595 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026, to investigate immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapies. The project, titled R21CA307817, addresses a serious complication of CAR T-cell treatment for refractory B-cell malignancies. ICANS manifests as cognitive impairment and cerebral edema and remains poorly understood, limiting...
- The National Cancer Institute awarded the University of Wisconsin–Madison $634,644 on March 12, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate treatment of neuroinflammation caused by chemoradiation-induced dysphagia in head and neck cancer patients. The funded research tests whether glibenclamide (GLC) therapy combined with tongue exercise can mitigate radiation-induced peripheral neuropathy and improve swallowing function in a rat model of chemoradiation...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,920 on March 11, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing) to conduct research on novel multi-targeted therapeutic strategies targeting T-cell lymphomas and their microenvironment. The funded work addresses chemotherapy-resistant T-cell lymphomas, where current treatments produce poor durable responses and clinical trial participation remains standard care. The...
- The National Institute of Neurological Disorders and Stroke awarded the University of Rochester $2,197,287 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Phase III confirmatory clinical trial of daily, wireless, home-based transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN). The trial will evaluate TENS efficacy in relieving neuropathic pain in cancer patients who have developed CIPN—a common...
- The National Cancer Institute awarded the University of California, Los Angeles $368,156 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate radiation-induced cellular reprogramming in the developing human brain and identify neuroprotective interventions. The research addresses cognitive decline following cranial radiotherapy for brain tumors by testing the hypothesis that radiation drives neural stem and progenitor cells to transdifferentiate into...
- The National Institutes of Health National Cancer Institute awarded $665,449 to the University of Pittsburgh on July 3, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of sensory nerve innervation in regulating anti-tumor immunity in melanoma. The research examines how sensory neurons that innervate melanoma tumors and their associated tumor-draining lymph nodes modulate immune responses within the tumor microenvironment and secondary lymphoid organs. The...
- The National Cancer Institute awarded New York University $595,993 on July 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a platform technology that enables direct and selective manipulation of intracellular molecules, particularly driver oncoproteins and their interactions, with the long-term goal of addressing undruggable targets in cancer....